Investing.com - The Federal Trade Commission (FTC) is gearing up to sue the top three pharmacy-benefit managers (PBMs) over their strategies for negotiating drug prices, including insulin. This follows a two-year investigation into whether these companies are directing patients away from more affordable medications. According to sources close to the matter, the FTC is planning to file lawsuits targeting business practices related to rebates negotiated with drug manufacturers. The agency is also investigating the role that insulin manufacturers play in these negotiations. PBMs oversee prescription-drug transactions for insurers and employers, negotiating discounts with drug manufacturers on behalf of these clients. The three largest PBMs—OptumRx, a part of Unitedhealth Group (NYSE:UNH); Express Scripts (NASDAQ:ESRX), owned by Cigna Corp (NYSE:CI); and CVS Health Corp (NYSE:CVS) Caremark, manage approximately 80% of US prescriptions. Under pressure from Sanders and other legislators, Eli Lilly and Company (NYSE:LLY), Sanofi (EPA:SASY), and Novo Nordisk (NYSE:NVO) (CSE:NOVOb) also committed to significant price reductions on insulin last year. They now provide coupons enabling many uninsured and commercially insured patients to access insulin for $35 a month. The prices of insulin, a vital treatment for diabetes, saw consistent annual increases from 2010 to 2019, according to a study published last year in JAMA Network Open. However, since 2015, Pharmacy Benefit Managers (PBMs) have negotiated discounts, effectively reducing net prices. Senator Bernie Sanders, an Independent from Vermont, criticized PBMs last year for allegedly prioritizing insulin products that offered them larger rebates, rather than focusing on those that were more cost-effective for patients. Pharmaceutical company Lilly revealed that it launched a more affordable version of its popular insulin, but fewer insurers offered coverage for it as PBMs favored the larger rebates associated with the pricier version. In 2022, President Biden enacted legislation that caps out-of-pocket payments for insulin at $35 a month for Medicare patients. ⚠️Stay up to date with the latest company news using InvestingPro! Our Summer Sale is now on, click here to save over 50%!⚠️ The Federal Trade Commission (FTC) released an interim report on Tuesday, documenting the findings of a two-year investigation into whether PBMs end up driving up costs for their clients and, in some cases, patients at pharmacy counters. FTC Chair Lina Khan stated that the agency's examination of PBMs is aimed at making healthcare more affordable. The companies criticized the report as flawed and misleading, maintaining that they save customers money. "FTC leadership has shown that they have predetermined conclusions that they want to advance," JC Scott, president of the Pharmaceutical Care Management Association, said in response to the FTC’s report. Federal law allows the FTC to prosecute companies for "unfair or deceptive" trade practices or "unfair methods of competition." Legislators in the House and Senate have proposed bills to regulate PBMs’ business practices, and lobbyists for drug manufacturers have implicated PBMs as the cause of escalating drug costs. Related Articles FTC to sue drug managers amid insulin price hikes AZZ Inc. Posts Strong Q1 Earnings Beat, Guidance Trails Consensus Costco to hike membership fees; shares jump
FTC to sue drug managers amid insulin price hikes
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...